Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7777433 | 0.84 | ACE2 (0.39) | ACE2OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL11303614 | 0.77 | OPRM1 (0.42) | ACE2OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL21889565 | 0.76 | ACE2 (0.36) | ACE2OPRM1PTPN1 | |
| SCHEMBL21834436 | 0.76 | ACE2 (0.36) | ACE2OPRM1PTPN1 | |
| SCHEMBL21889564 | 0.76 | ACE2 (0.36) | ACE2OPRM1PTPN1 | |
| SCHEMBL31290335 | 0.76 | LMNA (0.40) | ACE2OPRM1 | |
| SCHEMBL14279103 | 0.74 | ACE2 (0.35) | ACE2OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL6400426 | 0.70 | ACE2 (0.36) | ACE2OPRM1PTPN1 | |
| SCHEMBL12977506 | 0.68 | OPRM1 (0.38) | ACE2OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL12977503 | 0.68 | OPRM1 (0.38) | ACE2OPRM1PTPN1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165559-A1 | Compounds Having a Physiological Effect | V. MANE FILS (FR) | 2012-06-28 | — | — | US | claimed |
| US-20120165559-A1 | Compounds Having a Physiological Effect | V. MANE FILS (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165559-A1 | Compounds Having a Physiological Effect | NPPA, CYP11B2, SHBG | ACE2 327/4885OPRM1 615/4885P2RX4 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.